The need for a personalized approach for prostate cancer management

BMC Medicine

Jack A Schalken¹  JP Michiel Sedelaar¹ 

[1] Radboud University Medical Center, Nijmegen, The Netherlands

关键词: Prostate cancer;    Prognosis;    Individualized medicine;    Genome;    Biomarker;   

Others  :  1203889
DOI  :  10.1186/s12916-015-0344-1

 received in 2015-04-08, accepted in 2015-04-08,  发布年份 2015

【 摘 要 】

The stratification of patients for treatment of prostate cancer is based on very general parameters like prostate-specific antigen, Gleason score, and TNM classification. We use these rough parameters for selection of active surveillance, active treatment, and even for the treatment selection in metastasized or castration-resistant prostate cancers. Up to now, we have not used individualized genetic classifiers for detailed sub-stratification, thus treating all patients as equal, and being only moderately successful. With the expected increase in systemic treatments, there is an apparent need for such classifiers. We will address these needs in this short commentary.

【 授权许可】

   
2015 Sedelaar and Schalken; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 2005; 15:187-95.
• [2]Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL et al.. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004; 350:2239-46.
• [3]Birnbaum JK, Feng Z, Gulati R, Fan J, Lotan Y, Wei JT et al.. Projecting benefits and harms of novel cancer screening biomarkers: a study of PCA3 and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2015; 24:677-82.
• [4]Loeb S, Bruinsma SM, Nicholsen J, Briganti A, Pickles T, Kakehi Y et al.. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol. 2015; 67:619-26.
• [5]Naoi Y, Noguchi S. Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer. 2015 [Epub ahead of print].
• [6]Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnager S et al.. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013; 31:1428-34.
• [7]Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2014. Epub ahead of print.
• [8]Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY et al.. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015; 33:944-51.